Global Polycystic Ovarian Syndrome (PCOS) Treatment Market Segmentation, By Drugs (Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants, Anti-Obesity), Surgery (Wedge Resection, Laparoscopic Drilling), End User (Hospital, Ambulatory Surgical Centers, Others) – Industry Trends and Forecast to 2031.
Polycystic Ovarian Syndrome (PCOS) Treatment Market Analysis
The increased prevalence of polycystic ovarian syndrome will help the polycystic ovarian syndrome (PCOS) treatment market to grow dramatically as the increased cases of polycystic ovarian syndrome, will increase the demand for the effective treatment procedure and medications, thus benefitting the market positively. According to the Centers for Disease Control and Prevention, approximately 5 million women of reproductive age have polycystic ovarian syndrome. The surge in cases will therefore directly offer opportunities for market to grow lucratively over forecast period.
Polycystic Ovarian Syndrome (PCOS) Treatment Market Size
Global polycystic ovarian syndrome (PCOS) treatment market size was valued at USD 6.16 billion in 2023 and is projected to reach USD 9.81 billion by 2031, with a CAGR of 6.00% during the forecast period of 2024 to 2031.
Report Scope and Market Segmentation
|
Attributes
|
Polycystic Ovarian Syndrome (PCOS) Treatment Key Market Insights
|
|
Segmentation
|
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa
|
|
Key Market Players
|
Bayer AG (Germany), Allergan (Ireland), Merck & Co. (U.S.), Pfizer Inc. (U.S.), Amgen (U.S.), Agile Therapeutics (U.S.), Ferring B.V (U.S.), Addex Therapeutics (Switzerland), Mylan N.V. (U.S.), Lupin (India), Blairex Laboratories Inc.,(U.S.), Apothecus Pharmaceutical Corp(U.S.), Eli Lilly And Company (U.S.), Novartis AG (Switzerland), BIOCAD Global (Russia), Teva Pharmaceutical Industries Ltd., (Israel) and Johnson & Johnson Services, Inc. (U.S.)
|
|
Market Opportunities
|
|
Polycystic Ovarian Syndrome (PCOS) Treatment Market Definition
The polycystic ovarian syndrome (PCOS), is a hormonal condition that affects many women of childbearing age. Polycystic Ovary Syndrome (PCOS) is characterized by irregular or extended menstrual cycles and elevated amounts of male hormones. Although there is currently no cure for PCOS, numerous drugs are used to regulate the menstrual cycle and manage the symptoms of the condition. It is also caused due to high levels of androgens, low-grade inflammation, cysts in the ovaries, excess insulin and genetic disorders.
Polycystic Ovarian Syndrome (PCOS) Treatment Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints and challenges. All of this is discussed in detail as below:
Drivers
- Growing Burden Of Polycystic Ovarian Syndrome (PCOS)
The surging cases of polycystic ovarian syndrome (PCOS), across the world is the most significant factor driving the growth for this market. Additionally, the other factors, including rising prevalence of diabetes and obesity among women, increasing hormonal disorders in women, socioeconomic factors, change in sedentary lifestyle, and growing consumption of unhealthy diet, are also expected to accelerate the market's overall growth.
Furthermore, the expanding healthcare sector, adoption of combination drugs, and rising patient adoption are also expected to fuel market growth. Moreover, the rising awareness among the patients and doctors regarding the chronic diseases and hospital-acquired infections also cushions the market’s growth within the forecasted period. The focus of leading manufacturers on expanding their geographic presence is also projected to bolster the market's growth.
Opportunities
- Growing Investments and Advancements
Moreover, the technological advancements for detection of polycystic ovary syndrome and the growth in awareness about polycystic ovarian syndrome treatment are estimated to generate lucrative opportunities for the market. The untapped potential offered by developing economies combined with rise in adoption of polycystic ovarian syndrome treatment products will further offer numerous growth opportunities for the market.
Restraints/Challenges
- Side Effects Associated With Drugs
The drugs for treating polycystic ovary syndrome also have various side effects. The side effects associated with drugs such as cardiovascular risks, weight gain, abnormal glucose tolerance, increase insulin resistance and thromboembolic events are expected to obstruct market growth.
- Stringent Drug Approval Policies
Also, the lack of approved therapeutics and lack of FDA drug approval is projected to challenge the polycystic ovarian syndrome (PCOS) treatment market in the forecast period of 2024-2031.
Furthermore, the lack of specific treatment for this disorder along with the unknown etiology and pathophysiology of polycystic ovarian syndrome will also hamper overall growth for the market.
This polycystic ovarian syndrome (PCOS) treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the polycystic ovarian syndrome (PCOS) treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Post Covid-19 Impact on Polycystic Ovarian Syndrome (PCOS) Treatment Market
Healthcare industry was largely impacted by the outbreak of COVID-19. The polycystic ovarian syndrome (PCOS) treatment market does not stand back as it was also adversely affected by it as pandemic had repercussions for many surgical operations, including laparoscopic ovarian drilling The imposition of the lockdown and social distancing restrictions by the government to curb the COVID-19 pandemic outbreak, led to halt of various operations, supply chain disruptions, stifling business growth, suspensions of new developments and has affected the overall treatment procedure which have impacted the market negatively. The non-essential treatment surgeries or procedures were also suspended. According to Experts at the University of Birmingham, patients who have contracted coronavirus and undertake surgery are at an increased risk of postoperative mortality, and that all non-emergent surgeries should be avoided. However, to maintain normal surgical practices, regulatory authorities established a few guidelines unique to each profession that surgeons must implement and follow to continue to offer safe and effective care to their patients throughout the COVID-19 pandemic.
On the brighter side, with the decrease in COVID-19 patients, the restrictions of the government measures are likely to relax. This will help the market witness a slight increment post COVID-19, as normal surgical practices can occur according to few guidelines that surgeons must implement and follow to continue to offer safe and effective care to their patients throughout. Healthcare practitioners have been able to restart their surgery practices as a result of the new standards. As a result, it is envisaged that laparoscopic ovarian drilling treatments will resume their usual growth post- COVID.
Polycystic Ovarian Syndrome (PCOS) Treatment Market Scope
The polycystic ovarian syndrome (PCOS) treatment market is segmented on the basis of drugs, surgery and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drugs
- Oral Contraceptives
- Antiandrogen
- Insulin-Sensitizing Agents
- Antidepressants
- Anti-Obesity
Surgery
- Wedge Resection
- Laparoscopic Drilling
End User
- Hospital
- Ambulatory Surgical Centers
- Others
Polycystic Ovarian Syndrome (PCOS) Treatment Market Regional Analysis
The polycystic ovarian syndrome (PCOS) treatment market is analyzed and market size insights and trends are provided by country, drugs, surgery and end user as referenced above.
The countries covered in the polycystic ovarian syndrome (PCOS) treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the polycystic ovarian syndrome (PCOS) treatment market because of the high awareness and the availability of advanced healthcare facilities within the region.
Asia-Pacific is expected to witness significant growth during the forecast period of 2024 to 2031 due to the government initiatives to raise awareness about the symptoms and diagnosis of PCOS and available treatment, which are increasing the number of women diagnosed with this syndrome within the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Polycystic Ovarian Syndrome (PCOS) Treatment Market Share
The polycystic ovarian syndrome (PCOS) treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to polycystic ovarian syndrome (PCOS) treatment market.
Polycystic Ovarian Syndrome (PCOS) Treatment Market Leaders Operating in the Market Are:
- Bayer AG (Germany)
- Allergan (Ireland)
- Merck & Co (U.S.)
- Pfizer Inc (U.S.)
- Amgen (U.S.)
- Agile Therapeutics (U.S.)
- Ferring B.V. (U.S.)
- Addex Therapeutics (Switzerland)
- Mylan N.V. (U.S.)
- Lupin (India)
- Blairex Laboratories Inc (U.S.)
- Apothecus Pharmaceutical Corp (U.S.)
- Eli Lilly And Company (U.S.)
- Novartis AG (Switzerland)
- BIOCAD Global (Russia)
- Teva Pharmaceutical Industries Ltd (Israel)
- Johnson & Johnson Services, Inc (U.S.)
Latest Developments in Polycystic Ovarian Syndrome (PCOS) Treatment Market
- In January 2020, Abbvie had a clinical trial in the works with the chemical Elagolix, which is being tested for safety and efficacy in women with polycystic ovary syndrome. The business is now conducting a Phase 2 multicenter, double-blind, randomised, placebo-controlled research to evaluate Elagolix's safety and efficacy in women with polycystic ovarian syndrome (PCOS).
- In Jan 2020, Evotec SE and Bayer AG launched a new five-year multi-target collaboration with Celmatix Inc. to develop various clinical candidates for the treatment of polycystic ovarian syndrome, which is projected to drive the market during the forecast period.
SKU-